Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Show more

3027 Townsgate Road, Westlake Village, CA, 91361, United States

https://www.arcutis.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

3.223B

52 Wk Range

$11.75 - $31.77

Previous Close

$26.31

Open

$26.08

Volume

770,526

Day Range

$26.08 - $27.02

Enterprise Value

2.467B

Cash

191.1M

Avg Qtr Burn

-1.754M

Insider Ownership

1.67%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZORYVE® (Roflumilast foam 0.3%) Details Seborrheic dermatitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (roflumilast) Topical Foam 0.3% Details Plaque Psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Plaque psoriasis (Ages 6 to 11)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Plaque psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Atopic Dermatitis (Ages 2 to 5)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Atopic dermatitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (roflumilast) Cream 0.3% Details Plaque psoriasis (Ages 2 to 5)	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream 0.05% Details Atopic dermatitis	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor) Details Hidradenitis Suppurativa	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor) Details Hidradenitis Suppurativa	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor) Details Vitiligo	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor) Details Vitiligo	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-234 Details Moderate to severe atopic dermatitis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-252 (JAKi) Details Vitiligo	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-255 topical ivarmacitinib Details Alopecia areata	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-252 (JAK1i) Details Skin disease/disorder, Eczema	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.